New malaria prevention combo tested in mali infants
NCT ID NCT06461026
First seen Nov 01, 2025 · Last updated Jun 11, 2026 · Updated 36 times
Summary
This study tests the safety of an experimental medicine called L9LS in infants aged 1 to 12 months in Mali. It also looks at how L9LS affects the immune response to a malaria vaccine called R21/Matrix-M. The goal is to find a better way to prevent malaria in young children.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Faladje MRTC Clinic
Faladié, Koulikoro, Mali
-
Kalifabougou MRTC Clinic
Kalifabougou, Koulikoro, Mali
-
Torodo MRTC Clinic
Torodo, Koulikoro, Mali
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.